Phase III SIERRA trial has positive full data results in active, relapsed or refractory AML

Mission Bio develops single-cell MRD assay

Mission Bio has developed a single-cell measurable residual disease assay that aims to advance personalized healthcare for patients with blood cancer.

September 29, 2023

Vol.49 No.36

Clinical Roundup

Vitamin C, D supplements led to fewer complications in AML, no OS benefit

Patients with acute myeloid leukemia who received vitamin C and D supplements while undergoing intensive chemotherapy had lower rates of complications, such as infections, bleeding, and inflammation, when compared with similar, previously treated patients who did not receive these supplements.

September 15, 2023

Vol.49 No.34

Drugs & Targets

FDA places partial clinical hold for magrolimab studies in AML

FDA has placed a partial clinical hold on the initiation of new patients in U.S. studies evaluating magrolimab to treat acute myeloid leukemia.

September 08, 2023

Vol.49 No.33

In Brief

City of Hope receives $32.3M from CIRM

Researchers at City of Hope were awarded $32.3 million from the California Institute for Regenerative Medicine to support three novel phase I clinical trials evaluating innovative cell and gene therapy treatments for patients with acute myeloid leukemia and other diseases.

August 11, 2023

Vol.49 No.32

Drugs & Targets

FDA approves quizartinib for newly diagnosed AML

FDA has approved quizartinib (Vanflyta) with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test.

July 21, 2023

Vol.49 No.29

Clinical Roundup

MD Anderson research: combination therapies for BRAF V600E mutations, cancer biomarkers in extracellular vesicles, and strategies for overcoming treatment resistance in lung cancer and AML

MD Anderson Cancer Center researchers have identified recent developments in effective combination therapies for patients with BRAF V600E mutations, an approach to identify cancer biomarkers in extracellular vesicles, therapeutic strategies for improving treatment responses in non-small cell lung cancer, and a novel combination therapy to overcome treatment resistance in a subset of patients with acute myeloid leukemia.

April 21, 2023

Vol.49 No.16

Phase III SIERRA trial has positive full data results in active, relapsed or refractory AML

YOU MAY BE INTERESTED IN

Mission Bio develops single-cell MRD assay

Vitamin C, D supplements led to fewer complications in AML, no OS benefit

FDA places partial clinical hold for magrolimab studies in AML

City of Hope receives $32.3M from CIRM

FDA approves quizartinib for newly diagnosed AML

MD Anderson research: combination therapies for BRAF V600E mutations, cancer biomarkers in extracellular vesicles, and strategies for overcoming treatment resistance in lung cancer and AML

Renew today!

Subscriber content

Login